Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Research output: Contribution to journal › Journal article › Research › peer-review
The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.
Original language | English |
---|---|
Journal | Lancet |
Volume | 379 |
Issue number | 9835 |
Pages (from-to) | 2429-38 |
Number of pages | 10 |
ISSN | 0140-6736 |
DOIs | |
Publication status | Published - 2012 |
ID: 48451543